μ-opiate receptor agonist loperamide blocks bethanechol-induced gallbladder contraction, despite higher cholecystokinin plasma levels in man

Neurogastroenterology and Motility

Volumn 17, Issue 5, 2005, Pages 761-766

  Otto, Bärbel ^a   Mawe, G M ^b   Riepl, R L ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF VERMONT   (United States)

^c Kreiskrankenhaus Erding ^*  (Germany)

Author keywords

opiate; Bethanechol; Cholecystokinin; Gallbladder motility; Loperamide; Pancreatic polypeptide

Indexed keywords

BETHANECHOL; CHOLECYSTOKININ; GASTRIN; GLYCOCHOLIC ACID; LOPERAMIDE; MOTILIN; MU OPIATE RECEPTOR AGONIST; NEUROTENSIN; PANCREAS POLYPEPTIDE; PLACEBO;

ADULT; ARTICLE; BILIARY EXCRETION; CHOLECYSTOKININ BLOOD LEVEL; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; GALLBLADDER CONTRACTION; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGUS TONE;

ADULT; BETHANECHOL; CHOLECYSTOKININ; CROSS-OVER STUDIES; GALLBLADDER; HUMANS; LOPERAMIDE; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PANCREATIC POLYPEPTIDE; PLACEBOS; RECEPTORS, OPIOID, MU;

EID: 25844447595     PISSN: 13501925     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2005.00694.x     Document Type: Article

References (33)

1. Giagnoni G, Casiraghi L, Senini R. Loperamide: evidence of interaction with μ and δ opiod receptors. Life Sci 1993; 33: 315-8.
2. Awouters F, Megens A, Verlinden M, Schuurkes J, Niemegeers C, Janssen PAJ. Loperamide: survey of studies on mechanism of its antidiarrheal activity. Dig Dis Sci 1993; 38: 977-95.
3. Kuge T, Shibata T, Willett S. Multicenter, double-blind, randomized comparison of wood creosote, the principal active ingredient of seirogan, an herbal antidiarrheal medication, and loperamide in adults with acute non-specific diarrhea. Clin Ther 2004; 26: 1644-51.
4. Dumitrascu DL, Stanculete M, Mitrea I, Dumitrascu DM, Farcas A. The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea. Rom J Intern Med 2004; 42: 191-7.
5. Riepl RL, Reichardt B, Auernhammer CJ et al. Suppression of vagus-mediated pancreatic polypeptide release by the μ-opiate receptor agonist loperamide. Br J Clin Pharmacol 1996; 46: 371-7.
6. Wood JD, Galligan JJ. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 2004; 16: 17-28.
7. Hopman WP, Rosenbusch G, Jansen JB, Lamers CB. Effect of increasing oral doses of loperamide on gallbladder motility in man. Br J Clin Pharmacol 1990; 29: 55-60.
8. Marzio L. Factors affecting gallbladder motility: drugs. Dig Liver Dis 2003; 35: S17-9.
9. Thimister PW, Hopman WP, van Roermund RF et al. Inhibition of pancreaticobiliary secretion by loperamide in humans. Hepatology 1997; 26: 256-61.
10. Tobin PJ, Hong Y, Scale JP, Rivory LP, McLachlan AJ. Loperamide inhibits the biliary excretion of iriotecan (CPT-11) in the rat isolated perfused liver. J Pharm Pharmacol 2005; 57: 39-45.
11. Guarraci FA, Pozo MJ, Palomares SM, Firth TA, Mawe GM. Opioid agonists inhibit excitatory neurotransmission in ganglia and at the neuromuscular junction in guinea pig gallbladder. Gastroenterology 2002; 122: 340-51.
12. Ooms LAA, Degryse AD, Janssen PAJ. Mechanism of action of loperamide. Scand J Gastroenterol 1984; 96: 145-55.
13. Riepl RL, Reichardt B, Rauscher J, Tzavella K, Lehnert P. Mediators of exocrine pancreatic secretion induced by intraduodenal application of bile and taurodeoxycholate in man. Eur J Med Res 1997; 96: 23-9.
14. Riepl RL, Lehnert P, Scharl A et al. Effect of intraduodenal bile and Na-taurodeoxycholate on exocrine pancreatic secretion and on plasma levels of secretin, pancreatic polypeptide, and gastrin in man. Scand J Gastroenterol 1990; 25: 45-53.
15. Jaffe JH, Kanzler M, Green T. Abuse potential of loperamide. Clin Pharmacol Ther 1980; 28: 812-9.
16. Pozo MJ, Camello PJ, Mawe GM. Chemical mediators of gallbladder dysmotility. Curr Med Chem 2004; 11: 1801-12.
17. Mawe GM, Moses PL, Pozo MJ. Motility of the biliary tree. In: Yamada T, ed. Textbook of Gastroenterology, 4th edn. Philadelphia, USA: Lippincott Williams and Wilkins, 2003: 248-65.
18. Smythe A, Ahmed R, Fitzhenry M, Johnson AG, Majeed AW. Bethanechol provocation testing does not predict symptom relief after cholecystectomy for acalculous biliary pain. Dig Liver Dis 2004; 36: 682-6.
19. Schwartz TW. Pancreatic polypeptide: a hormone under vagal control. Gastroenterology 1993; 85: 1411-25.
20. Hopman WP, Kerstens PJ, Jansen JB, Rosenbusch G, Lamers CB. Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output. Gastroenterology 1985; 89: 1242-7.
21. Masclee AA, Hopman WP, Corstens FH, Rosenbusch G, Jansen JB, Lamers CB. Simultaneous measurement of gallbladder emptying with cholescintigraphy and US during infusion of physiologic doses of cholecystokinin: a comparison. Radiology 1989; 173: 407-10.
22. Malave A, Yim GK. Effects of chronic morphine on biliary tract responses to cholecystokinin-octapeptide in female guinea pigs. Life Sci 1993; 52: 695-700.
23. Shimoyama M, Kito S. Effect of cerulein on in vivo release of acetylcholine from the rat striatum. Brain Res 1989; 492: 381-4.
24. Fraser KA, Davison JS. Cholycystokinin-induced c-fos expression in the rat brain stem is influenced by vagal nerve integrity. Exp Physiol 1992; 77: 225-8.
25. Mawe GM, Gokin AP, Wells DG. Actions of cholecystokinin and norepinephrine on vagal inputs to ganglionic cells in guinea pig gallbladder. Am J Physiol 1994; 267: G1146-51.
26. Sigh M. Effect of endorphins on amylase secretion from rat pancreas in vivo and in vitro. Dig Dis Sci 1985; 30: 257-62.
27. Dashwood MR, Muddle JR, Spyer MK. Opiate receptor subtypes in the nucleus tractus solitarii of the cat: the effect of vagal section. Eur J Pharmacol 1988; 155: 82-92.
28. Grundy D, Booth CE, Winchester W, Hicks GA. Peripheral opiate action on afferent fibres supplying the rat intestine. Neurogastroenterol Motil 2004; 16: 29-37.
29. Koop I, Koop H, Gerhardt C, Schafmayer A, Arnold R. Do bile acids exert a negative feedback control of cholecystokinin release? Scand J Gastroenterol 1989; 24: 315-20.
30. Koop I, Schindler M, Bosshammer A, Scheibner J, Stange E, Koop H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 1996; 39: 661-7.
31. Fletcher P, Steffen R, DuPont H. Benefit/risk considerations with respect to OTC-descheduling of loperamide. Arzneimittelforschung 1995; 45: 608-13.
32. Marcus SN, Heaton KW. Intestinal transit, deoxycholic acid and the cholesterol saturation of bile - three interrelated factors. Gut 1986; 27: 550-8.
33. Lifchitz AL, Virkel GL, Sallovitz JM, Pis A, Imperiale FA, Lanusse CE. Loperamide modifies the tissue disposition kinetics of ivermectin in rats. J Pharm Pharmacol 2004; 56: 61-7.